Dolutegravir-Related Neurological Adverse Events : A Case Report of Successful Management with Therapeutic Drug Monitoring

Copyright© Bentham Science Publishers; For any queries, please email at epubbenthamscience.org..

OBJECTIVE: Dolutegravir (DTG), a highly effective second-generation HIV integrase inhibitor with high genetic barrier to resistance, has shown excellent tolerability and safety profiles in clinical trials. However, some patients may experience neurological or psychiatric adverse effects leading to DTG discontinuation.

CASE REPORT: This report describes a case of 29-year-old woman who developed neurological adverse events after starting the DTG-based antiretroviral therapy. Serum DTG concentrations were supratherapeutic which has required a dosing interval adjustment. The findings of this case report suggest that Therapeutic Drug Monitoring might be useful in individuals expressing unusual DTG pharmacokinetics.

Medienart:

E-Artikel

Erscheinungsjahr:

2018

Erschienen:

2018

Enthalten in:

Zur Gesamtaufnahme - volume:13

Enthalten in:

Current drug safety - 13(2018), 1 vom: 01., Seite 69-71

Sprache:

Englisch

Beteiligte Personen:

Parant, Francois [VerfasserIn]
Miailhes, Patrick [VerfasserIn]
Brunel, Florence [VerfasserIn]
Gagnieu, Marie-Claude [VerfasserIn]

Links:

Volltext

Themen:

Adverse events
Antiretroviral
Case Reports
DKO1W9H7M1
Dolutegravir
HIV Integrase Inhibitors
Heterocyclic Compounds, 3-Ring
INSTI.
Journal Article
Oxazines
Pharmacokinetics
Piperazines
Pyridones
Therapeutic drug monitoring

Anmerkungen:

Date Completed 20.09.2018

Date Revised 09.12.2020

published: Print

Citation Status MEDLINE

doi:

10.2174/1574886313666180116124046

funding:

Förderinstitution / Projekttitel:

PPN (Katalog-ID):

NLM280074743